Explore 3 Stock Ideas & Industry Insights Download Free Report

General News

Why Is Caesars (NASDAQ:CZR) Oversold at RSI 21.3 With a USD 31 Cash Buyout Pending?

The stake is unusual: the stock is oversold on a momentum gauge while tethered to a contractual cash price. Caesars (NASDAQ:CZR) is priced against USD 31.00 in cash, so the USD 1.93 spread is own arithmetic on two numbers and equals 6.6% of the …

Vinay Lochav | 16 October 2026

Why Is ManpowerGroup (NYSE:MAN) Oversold at RSI 21.9 After Shares Fell 19.71% in a Week?

The tension is that EPS beat last year's figure by 21.7% yet the stock fell. ManpowerGroup (NYSE:MAN) traded down 14.9% to USD 44.22 intraday on October 15, 2026 per published market data, and the weekly decline is 19.71% in the table. Reported EPS was …

Vinay Lochav | 16 October 2026

Why Is Backblaze (NASDAQ:BLZE) Oversold at RSI 23.5 After a 29.62% Weekly Drop?

The market is pricing a reset from a steep run, not a filing. The 52-week range is USD 3.26 to USD 23.99, and the stock was up 107.51% year to date at the October 14 intraday price of USD 9.67. Backblaze (NASDAQ:BLZE) traded as …

Vinay Lochav | 16 October 2026

Why Did State Street (NYSE:STT) Fall 6.5% After 33% EPS Growth, Leaving RSI at 24.1?

The market was pricing perfection, and the print offered a rounding error. EPS of USD 3.69 compared with a USD 3.68 consensus, while revenue of USD 4.004 billion missed USD 4.04 billion. Analysts pressed management on why net interest income guidance was not stronger, …

Vinay Lochav | 16 October 2026

Why Did Candel Therapeutics (NASDAQ:CADL) Lose 9.9% in a Week Before Its Planned Q4 Prostate Cancer Filing?

The market is weighing a binary filing against a financing overhang. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026; the weekly decline followed four scientific releases between September 30 and October 2, none negative. The October 15 …

Vinay Lochav | 16 October 2026

Why Is Travere Therapeutics (NASDAQ:TVTX) Oversold at RSI 28.9, 26% Below Its 52-Week High?

The market is asking whether a launch story can survive a leadership handover. Filspari, the company's kidney drug, gained a focal segmental glomerulosclerosis indication in April 2026, and revenue nearly doubled. The shares nonetheless closed October 15 at USD 52.79 and traded at USD …

Vinay Lochav | 16 October 2026

Why Is Oruka Therapeutics (NASDAQ:ORKA) Oversold, Only 1% Above Its USD 72.50 Offering Price?

The tension is that strong data and a strong balance sheet have not held the price. The 52-week range is USD 25.11 to USD 115.52, so the stock is 36.6% below its high and 2.9 times its low (own arithmetic). The Week 28 results …

Vinay Lochav | 16 October 2026

Why Did Target Hospitality (NASDAQ:TH) Fall 14.1% in a Week as Sponsor Share Sales Continue?

The market is weighing growth against share supply. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026 for the October 15 decline. The pattern is a sponsor selling ladder: 8.05 million shares at USD 14.00 in April, 7.0 …

Vinay Lochav | 16 October 2026

Why Has V.F. Corporation (NYSE:VFC) Rallied 13.6% in a Week, Pushing RSI to 79.8?

The market is paying for a Vans recovery earnings have not shown. The driver is a cluster of upgrades: JPMorgan on October 9, Piper Sandler and Truist on October 13, and Barclays raised its target to USD 24. The stock closed October 15 at …

Vinay Lochav | 16 October 2026

Why Did Portillo's (NASDAQ:PTLO) Rise 23.46% in a Week Without an Identified Catalyst?

The market added 23.46% to Portillo's in five sessions, yet the company filed nothing that changes its outlook. The implied price a week ago was USD 3.90 (own arithmetic on two published numbers). On October 15, 2026, midday volume was 2.41 million shares against …

Vinay Lochav | 16 October 2026
Support

Hi! How can we help you today?

Loading…